Evidence map›Paper›PMID 24579063›Full record

ArticlePublic health action2012

Effect of universal MODS access on pulmonary tuberculosis treatment outcomes in new patients in Peru.

A Mendoza-Ticona, E Alarcón, V Alarcón, K Bissell, E Castillo, I Sabogal, J Mora, D Moore, A D Harries

Abstract read
In one paragraph

Article in Public health action, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017
    Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A Mendoza-TiconaUSAID/Peru Quality Healthcare Project, Lima, Peru.
E AlarcónInternational Union Against Tuberculosis and Lung Disease, Paris, France.
V AlarcónEstrategia Sanitaria Nacional de Prevención y Control de la Tuberculosis, Ministerio de Salud, Lima, Peru.
K BissellInternational Union Against Tuberculosis and Lung Disease, Paris, France ; The University of Auckland, Auckland, New Zealand.
E CastilloDirección Regional de Salud de Callao, Callao, Peru.
I SabogalInstituto de Medicina Tropical 'Daniel A. Carrión', Universidad Nacional Mayor de San Marcos, Lima, Peru.
J MoraDirección Regional de Salud de Callao, Callao, Peru.
D MooreLondon School of Hygiene & Tropical Medicine, London, UK.
A D HarriesInternational Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.

Funding

Peru ICOHRTA Network for AIDS/TB Research TrainingU2RTW007368 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI GOTUZZO, EDUARDO · 2007 to 2011
$1.8M
FIC NIH HHS U2R TW007368
6 · The paper itself

Abstract

settingPrimary health care centres in Callao, Peru.

objectivesTo evaluate the effect of universal access to the microscopic-observation drug susceptibility (MODS) assay on treatment outcomes in new and primary multidrug-resistant tuberculosis (MDR-TB) patients and on the process of drug susceptibility testing (DST).

designRetrospective review of tuberculosis (TB) registers and clinical records before (2007) and after (2009) the introduction of MODS in 2008.

resultsThere were 281 patients in each cohort. Favourable treatment outcomes for 2007 (81%) and 2009 (77%) cohorts were similar. There was an increase in loss to follow-up (from 6% to 10%,

conclusionUniversal access to MODS increased DST coverage, reduced the time required to obtain DST results and was associated with reduced failure rates. MODS can make an important contribution to TB management and control in Peru.

Indexed as

drug-resistant TBMDR-TBMODSoperational researchPerurapid test

Identifiers

PMID24579063
PMCPMC3933568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.